CAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC) today announced the
appointment of Daniella Beckman to
its board of directors. Ms. Beckman, who is currently the Chief
Financial Officer of Tango Therapeutics and board member for Vor
Biopharma and 5:01 Acquisition Corp, brings more than 20 years of
corporate strategy, finance and business operations experience.
"Daniella's wealth of experience in the biopharmaceutical sector
brings new strength to our Board of Directors," said Jeff Albers, Chief Executive Officer and
Chairman of the Board of Directors of Blueprint Medicines. "We
welcome her perspective and expertise as we continue our evolution
as a global leader in precision therapy."
"Blueprint Medicines has achieved impressive business results
and impact for patients in its first 10 years, with two approved
medicines, a broad pipeline and a fully integrated global
business," said Ms. Beckman. "I'm excited to join the company at
the precipice of its next wave of growth, and I look forward to
working with management and other board members to realize the
promise of precision medicine for even more patients with
significant medical needs."
Ms. Beckman joins Blueprint Medicines with deep financial and
operational experience across the biotechnology industry, having
worked with both private and publicly traded companies throughout
her career. At Tango Therapeutics, Ms. Beckman oversees finance,
investor relations, and business development. Prior to joining
Tango, Ms. Beckman was a consultant to early-stage biotechnology
companies, leading financial activities and building companies'
financial infrastructures. She also served as Interim Chief
Financial Officer for Neon Therapeutics. Previously, Ms. Beckman
was Chief Financial Officer of Idenix Pharmaceuticals, where she
was responsible for finance, investor relations, and IT until the
company was acquired by Merck in 2014. Earlier in her career, she
held various finance positions at Coley Pharmaceuticals, Biogen
Idec, and PricewaterhouseCoopers (PwC). Ms. Beckman received her BA
in business administration and accounting from Boston University. Ms. Beckman also serves as Chair
of the Audit Committee and member of the Compensation Committee for
the Board of Directors of Vor Biopharma, Chair of the Audit
Committee and member of the Nomination and Governance Committee for
the Board of Directors of 5:01 Acquisition Corp, and previously
served as Chair of both the Audit and the Nomination and Governance
Committees for the Board of Directors of Translate Bio.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and
hematologic disorders. Applying an approach that is both precise
and agile, we create medicines that selectively target genetic
drivers, with the goal of staying one step ahead across stages of
disease. Since 2011, we have leveraged our research platform,
including expertise in molecular targeting and world-class drug
design capabilities, to rapidly and reproducibly translate science
into a broad pipeline of precision therapies. Today, we are
delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple
programs for genomically defined cancers, systemic mastocytosis,
and cancer immunotherapy. For more information,
visit www.BlueprintMedicines.com and follow us on Twitter
(@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, express or implied
statements regarding plans, strategies, timelines and expectations
for Blueprint Medicines' current or future approved drugs and drug
candidates, including timelines for marketing applications and
approvals, the initiation of clinical trials or the results of
ongoing and planned clinical trials; Blueprint Medicines' plans,
strategies and timelines to nominate development candidates; plans
and timelines for additional marketing applications
for avapritinib and pralsetinib and, if approved, commercializing
avapritinib and pralsetinib in additional geographies or for
additional indications; the potential benefits of any of Blueprint
Medicines' current or future approved drugs or drug candidates in
treating patients; the potential benefits of Blueprint
Medicines' collaborations; timelines and expectations for the
proposed acquisition (including future performance and revenue);
and Blueprint Medicines' strategy, goals and anticipated financial
performance, milestones, business plans and focus. The words "aim,"
"may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend,"
"believe," "estimate,"
"predict," "project," "potential," "continue," "target" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to the impact of the
COVID-19 pandemic to Blueprint Medicines' business, operations,
strategy, goals and anticipated milestones, including Blueprint
Medicines' ongoing and planned research and discovery activities,
ability to conduct ongoing and planned clinical trials, clinical
supply of current or future drug candidates, commercial supply of
current or future approved products, and launching, marketing and
selling current or future approved products; Blueprint
Medicines' ability and plans in continuing to establish and expand
a commercial infrastructure, and successfully launching, marketing
and selling current or future approved products;
Blueprint Medicines' ability to successfully expand the approved
indications for AYVAKIT/AYVAKYT and GAVRETO or obtain marketing
approval for AYVAKIT/AYVAKYT in additional geographies in the
future; the delay of any current or planned clinical trials or the
development of Blueprint Medicines' current or future drug
candidates; Blueprint Medicines' advancement of multiple
early-stage efforts; Blueprint Medicines' ability to successfully
demonstrate the safety and efficacy of its drug candidates and gain
approval of its drug candidates on a timely basis, if at all; the
preclinical and clinical results for Blueprint Medicines' drug
candidates, which may not support further development of such drug
candidates; actions of regulatory agencies, which may affect the
initiation, timing and progress of clinical trials; Blueprint
Medicines' ability to obtain, maintain and enforce patent and other
intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or
any drug candidates it is developing; Blueprint Medicines' ability
to develop and commercialize companion diagnostic tests for
AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug
candidates; Blueprint Medicines' ability to complete the proposed
acquisition in a timely manner or at all; the occurrence of any
event, change or other circumstances that could give rise to the
termination of the proposed acquisition; and the success of
Blueprint Medicines' current and future collaborations,
partnerships or licensing arrangements. These and other risks and
uncertainties are described in greater detail in the section
entitled "Risk Factors" in Blueprint Medicines' filings with the
Securities and Exchange Commission (SEC), including Blueprint
Medicines' most recent Annual Report on Form 10-K, as supplemented
by its most recent Quarterly Report on Form 10-Q and any other
filings that Blueprint Medicines has made or may make with the SEC
in the future. Any forward-looking statements contained in this
press release represent Blueprint Medicines' views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Except as required by law, Blueprint
Medicines explicitly disclaims any obligation to update any
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-appoints-daniella-beckman-to-its-board-of-directors-301441703.html
SOURCE Blueprint Medicines Corporation